Eurizon Capital SGR S.p.A. Makes New Investment in Genenta Science S.p.A. Unsponsored ADR $GNTA

Posted by Francis Steltz on Jun 4th, 2026

Eurizon Capital SGR S.p.A. bought a new position in shares of Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 360,000 shares of the company’s stock, valued at approximately $536,000.

Separately, Citadel Advisors LLC bought a new position in Genenta Science during the 3rd quarter worth about $41,000. 15.13% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Genenta Science in a report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Genenta Science has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on GNTA

Genenta Science Trading Down 4.1%

Shares of NASDAQ GNTA opened at $2.11 on Thursday. The business has a 50-day moving average of $0.77 and a 200-day moving average of $1.11. The company has a debt-to-equity ratio of 0.35, a quick ratio of 14.16 and a current ratio of 14.16. Genenta Science S.p.A. Unsponsored ADR has a fifty-two week low of $0.55 and a fifty-two week high of $10.00.

Genenta Science (NASDAQ:GNTA – Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.28.

About Genenta Science

(Free Report)

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.